Buy Opana ER 15mg inUK Online

Opana ER 15mg is an extended-release (ER) formulation of oxymorphone hydrochloride, a strong opioid analgesic that was developed for the management of severe, long-term pain requiring continuous, around-the-clock opioid treatment. The extended-release formulation is designed to release the medicine gradually over approximately 12 hours and is not intended for occasional or breakthrough pain. (FDA Access Data)

For readers in the United Kingdom, it is important to know that Opana ER is not licensed or routinely prescribed in UK clinical practice. The original Opana ER brand has also been discontinued in the United States, although some generic oxymorphone products have existed in certain markets. (Drugs.com)

What Is Opana ER 15mg?

Opana ER 15 mg contains:

• Active ingredient: Oxymorphone hydrochloride
• Strength: 15 mg
• Medicine class: Strong opioid analgesic
• Dosage form: Extended-release (modified-release) tablet

Oxymorphone is a semi-synthetic opioid that relieves pain by acting on opioid receptors in the brain and spinal cord.

How Does Opana ER Work?

Oxymorphone binds primarily to mu-opioid receptors, reducing the transmission of pain signals and changing how the brain perceives pain.

This may help:

• Relieve severe chronic pain
• Improve comfort in patients requiring long-term pain management
• Support daily functioning when pain is appropriately controlled

Because it affects the central nervous system, it can also cause sedation and slow breathing.

Medical Uses

Where it has been available, Opana ER was indicated for adults with pain that:

• Is severe enough to require around-the-clock opioid treatment
• Is expected to continue for an extended period
• Has not responded adequately to non-opioid medicines or other therapies

It is not appropriate for:

• Mild pain
• Short-term pain
• Occasional pain
• Breakthrough pain
• “As-needed” pain relief

Extended-release opioids should only be prescribed when the expected benefits outweigh their risks. (FDA Access Data)

Availability in the UK

Opana ER 15 mg is not licensed or routinely prescribed in the United Kingdom. If long-acting opioid treatment is required, UK healthcare professionals generally prescribe medicines that are licensed for UK use, depending on the patient’s condition and clinical needs. (nhs.uk)

How Should It Be Taken?

If prescribed in countries where oxymorphone ER is available:

• Take it exactly as directed by your healthcare professional.
• Swallow the tablet whole with water.
• Do not crush, chew, split, or dissolve the tablet.

Crushing or chewing an extended-release opioid tablet can release the full dose at once, greatly increasing the risk of overdose and life-threatening respiratory depression. (FDA Access Data)

Common Side Effects

Like other opioid medicines, oxymorphone may cause:

• Constipation
• Nausea
• Vomiting
• Drowsiness
• Dizziness
• Dry mouth
• Headache
• Sweating

Constipation is particularly common with opioid medicines and may require preventive measures recommended by a healthcare professional.

Serious Side Effects

Seek emergency medical attention immediately if someone develops:

• Difficulty breathing
• Slow or shallow breathing
• Extreme sleepiness or inability to wake
• Blue lips or fingertips
• Loss of consciousness
• Severe allergic reaction

These symptoms may indicate an opioid overdose or another life-threatening emergency. (DailyMed)

Dependence, Tolerance, and Addiction

Like all strong opioids, oxymorphone carries important risks, including:

• Tolerance, where the medicine becomes less effective over time.
• Physical dependence, where stopping suddenly can cause withdrawal symptoms.
• Opioid use disorder (addiction) in some people.

If long-term opioid therapy needs to be stopped, healthcare professionals usually recommend gradually reducing the dose rather than stopping abruptly. (FDA Access Data)

Drug Interactions

Oxymorphone may interact with:

• Other opioid medicines
• Benzodiazepines
• Sleeping tablets
• Alcohol
• Muscle relaxants
• Other medicines that cause drowsiness

These combinations can significantly increase the risk of profound sedation, dangerously slowed breathing, coma, and death.

Alcohol

Alcohol should be avoided while taking extended-release opioids because it can substantially increase the risk of:

• Severe drowsiness
• Respiratory depression
• Accidental overdose

(FDA Access Data)

Driving

Do not drive or operate machinery if oxymorphone causes:

• Sleepiness
• Dizziness
• Poor concentration
• Slowed reaction times

Driving while impaired by opioids is unsafe and may be unlawful.

Pregnancy and Breastfeeding

If you are pregnant, planning pregnancy, or breastfeeding, discuss treatment options with your healthcare professional before taking any opioid medicine. Long-term opioid use during pregnancy may lead to neonatal opioid withdrawal syndrome after birth, and opioid use during breastfeeding requires careful medical assessment. (FDA Access Data)

Storage

Store opioid medicines:

• In their original packaging.
• At room temperature.
• Away from heat and moisture.
• Securely and out of the sight and reach of children.

Return unused tablets to a pharmacy for safe disposal.

Frequently Asked Questions

Is Opana ER 15 mg available in the UK?
No. Opana ER is not licensed or routinely prescribed in the UK. (nhs.uk)

Can Opana ER be used for sudden pain?
No. It is intended only for continuous management of severe chronic pain, not for occasional or breakthrough pain. (FDA Access Data)

Can the tablet be crushed or split?
No. Extended-release tablets must always be swallowed whole because crushing, chewing, or splitting them can rapidly release the full dose and greatly increase the risk of overdose. (FDA Access Data)

Is the Opana ER brand still available?
The original Opana ER brand has been discontinued in the United States, although generic oxymorphone products have existed in some markets. (Drugs.com)

Key Takeaways

Opana ER 15 mg is an extended-release oxymorphone tablet developed for the treatment of severe, persistent pain requiring continuous opioid therapy when alternative treatments are inadequate. It is not licensed or routinely prescribed in the UK, and the original Opana ER brand has been discontinued in the United States. Like all strong opioids, it carries significant risks, including constipation, drowsiness, respiratory depression, dependence, addiction, and overdose. It should only be used under the supervision of a qualified healthcare professional, exactly as prescribed, and extended-release tablets should always be swallowed whole. (FDA Access Data)